Shionogi Reports Mixed Financial Performance for Q3 FY2024

Shionogi & Co ( (JP:4507) ) just unveiled an announcement.

Shionogi & Co., Ltd. reported a slight decline in revenue and operating profit for the first nine months of fiscal year 2024 compared to the same period the previous year. Despite this, the profit attributable to the owners of the parent increased by 5.2%, and comprehensive income decreased by 13.8%. The company completed a 3-for-1 stock split and maintained its annual dividend forecast, reflecting strategic financial management and stability. This financial update indicates a mixed performance with continued growth in profitability, despite challenges reflected in revenue and comprehensive income metrics.

More about Shionogi & Co

Shionogi & Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily involved in the pharmaceutical industry. The company focuses on developing and manufacturing medicines, with a notable presence in the market for infectious disease treatments and other therapeutic areas.

YTD Price Performance: 20.32%

Average Trading Volume: 531

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $13.36B

For detailed information about 4507 stock, go to TipRanks’ Stock Analysis page.